Evidence map›Paper›PMID 27440153›Full record

ArticleJournal of experimental & clinical cancer research : CR2016

SYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma.

Xiao Liu, Jiangjiao Zhou, Ning Zhou, Jianwei Zhu, Yong Feng, Xiongying Miao

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Current research of the Notch pathway in hepatocellular carcinoma.European journal of medical research · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. [Role of enolase 1 in hepatocellular carcinoma and possible mechanism].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2017
    Article
  7. Article
  8. LowerCancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xiao LiuDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Jiangjiao ZhouDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Ning ZhouHepatobiliary Surgery Department, Hunan Provincial People's Hospital, Changsha, Hunan, 410005, China.
Jianwei ZhuDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Yong FengDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China.
Xiongying MiaoDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. puwaimiaoxiongying@126.com.
Second Xiangya Hospital of Central South University · CNCentral South University · CNHunan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSynaptojanin 2 Binding Protein (SYNJ2BP) is essential to cell proliferation. Previous studies show that SYNJ2BP participates in sprouting angiogenesis, which plays an important part in several abnormal conditions including cancer. However, the activity of SYNJ2BP in hepatocellular carcinoma (HCC) has not been elucidated yet.

methodsFirstly, real-time PCR and western blotting (WB) were adopted to evaluate SYNJ2BP expressions in HCC tissues and HCC cell lines. Secondly, we did follow-up and prognostic study to explore the association of SYNJ2BP expression and HCC patients prognosis. Thirdly, we induced or silenced SYNJ2BP expression on selected HCC cell lines and explored the function of SYNJ2BP in vitro and in vivo. Lastly, we conducted Cignal Finder Cancer 10-Pathway Reporter Array in combination with loss- and gain-of-function assay to investigate potential mechanisms.

resultsThrough various techniques we found that SYNJ2BP was decreased in HCC tissues and HCC cell lines. The subsequent analysis showed that low expression of SYNJ2BP was associated with tumor size, tumor nodule number, vascular invasion, TNM stage and BCLC stage, and was an independent risk factor for survival of HCC. Later, the in vitro experiments demonstrated that SYNJ2BP inhibited HCC cells invasion, migration and proliferation, also the in vivo testing revealed that SYNJ2BP inhibited tumor growth and metastasis. Finally, we also uncovered that SYNJ2BP inhibited HCC growth and metastasis through activating DLL4-mediated Notch signaling pathway.

conclusionsCollectively, our data provide evidence that SYNJ2BP may act as a tumor suppressor during HCC development and could serve as a potential therapeutic target.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCalcium-Binding ProteinsCarcinoma, HepatocellularCarrier ProteinsCell Line, TumorCell MovementCell ProliferationHep G2 CellsHumansIntercellular Signaling Peptides and ProteinsLiver NeoplasmsMaleMembrane ProteinsMiceNeoplasm MetastasisAdaptor Proteins, Signal TransducingCalcium-Binding ProteinsCarrier ProteinsDLL4 protein, humanIntercellular Signaling Peptides and ProteinsMembrane ProteinsSYNJ2BP protein, humanDLL4Hepatocelluar carcinomaMetastasisPrognosisSYNJ2BP

Identifiers

PMID27440153
PMCPMC4955141
OpenAlexW2478378437

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.